Trinity Biotech plc (TRIB) Stock Forecast
TRIB analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $3.00 average of analyst targets
- Upside to target
- −62.6% from the latest close
- Next earnings
- —
- 52-week range
- $5.69 – $38.40
TRIB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TRIB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$1.09 | −$1.09 | −$1.09 | −$1.77 | +38.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TRIB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $59.5M | $59.5M | $59.5M | +25.3% | 1 |
TRIB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TRIB revenue: reported and forecast
TRIB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$0.49 | −$0.49 | −$0.49 | −$0.49 | −$1.09 | +122.4% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TRIB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TRIB beat in 4 of 11.
What analysts expect from TRIB
The average price target is $3.00, 62.6% below the latest close of $8.03. For 2026 the average estimate is −$1.09 per share on revenue of $59.5 million. Trinity Biotech beat the EPS estimate in 4 of the last 11 quarters.
Related: TRIB income statement, TRIB key metrics, TRIB chart. See the TRIB stock overview for the latest quote and news.
TRIB forecast FAQ
What is Trinity Biotech's price target?
The average analyst price target for Trinity Biotech is $3.00, 62.6% below the latest close of $8.03.
Does Trinity Biotech usually beat earnings estimates?
Trinity Biotech reported EPS at or above the analyst estimate in 4 of the last 11 quarters.